CHRNB4
MOLECULAR TARGETcholinergic receptor nicotinic beta 4 subunit
CHRNB4 (cholinergic receptor nicotinic beta 4 subunit) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CHRNB4
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Nicotine Nicotine is highly toxic alkaloid. It is | 4.84 | 126 |
| 2 | Mecamylamine | 2.40 | 10 |
| 3 | Lobeline | 1.95 | 6 |
| 4 | Dimethylphenylpiperazinium Iodide | 1.61 | 4 |
| 5 | Ibogaine | 1.39 | 3 |
| 6 | mg624 | 1.10 | 2 |
| 7 | Arecoline | 0.69 | 1 |
| 8 | Dihydro-beta-Erythroidine Dihydro analog of beta-erythroidine, which is isolated from | 0.69 | 1 |
| 9 | Ondansetron | 0.69 | 1 |
About CHRNB4 as a Drug Target
CHRNB4 (cholinergic receptor nicotinic beta 4 subunit) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented CHRNB4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CHRNB4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.